Levosimendan for Heart-Operated Patients: What is the State of the Art?

Author(s): Georgios I. Tagarakis, Nikolaos B. Tsilimingas

Journal Name: Recent Patents on Cardiovascular Drug Discovery
Continued as Recent Advances in Cardiovascular Drug Discovery

Volume 4 , Issue 1 , 2009


Acute heart failure is a common clinical problem faced in cardiac surgery operating rooms and intensive care units. Levosimendan, an inotropic and vasodilating agent used widely in cases of acute heart failure for “cardiological” patients, has not gained global acceptance in its application for heart-operated ones. Herein, we are presenting a series of studies and patents concerning this medication, which, in general, support the use of levosimendan during and after heart surgery, despite the relatively high cost of administration. However, trials with larger samples of patients have to be performed in order to definitively establish this medication as a routinely administered drug for acute congestive heart failure after heart surgery.

Keywords: Acute heart failure, levosimendan, inotropic agent, vasodilation and heart surgery

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [22 - 24]
Pages: 3
DOI: 10.2174/157489009787260052
Price: $65

Article Metrics

PDF: 17